After investigating the apparent link between dialysis product GranuFlo and cardiac arrest, Girard Gibbs has filed lawsuits in the federal and California state courts alleging a cover-up of this link by GranuFlo producer Fresenius.
GranuFlo is a dry acid product manufactured by Fresenius Medical Care for use in the dialysis process. It is used in Fresenius’ dialysis clinics, which treat more than a third of dialysis patients in the United States, as well as on an estimated 125,000 patients in clinics operated by other dialysis providers. As the Fresenius website states, this makes GranuFlo the “most-widely prescribed dry acid product in the dialysis industry.”
Unfortunately, GranuFlo may also be among the most dangerous of products used in the dialysis industry due to a potential risk of cardiac arrest. Data gathered by Fresenius on the 941 patients who suffered cardiac arrest inside Fresenius clinics in 2010 found a link between between GranuFlo and alkalosis- a condition of increasing levels of bicarbonate in a patient's blood- that appears to make dialysis patients six to eight times as likely to suffer sudden cardiac arrest. On November 4, 2011 Fresenius sent an internal memo to their medical clinics about this danger.